SBI, Infosys, Aurobindo Pharma And More - Top Stock Picks For May: KRChoksey

KRChoksey Research Report

Investment period: six months. Research idea: Fundamental

State Bank of India - SBI has positioned itself as one of the best-in-class players in the liability franchise market. With strong brand equity and a broad presence in India through its branches, the bank has a robust customer base for its deposits. The bank has built a strong balance sheet in the last few quarters, and we expect to see a strong current account and savings account mix with a focus on the retail segment, which will lead to a stable but gradual improvement in margins.

Infosys Ltd. - Infosys has signed $2.3 billion (48% of net new) worth deals in Q4 (up 10% YoY, down 9% QoQ), $9.6 billion (40% of net new) in FY22 versus $14.2 billion in FY21. Management is expecting some improvement in pricing from the current level going ahead on the back of a significant increase in amount being spent by banking, financial services and insurance clients.

Aurobindo Pharma Ltd. - The company is seeking funds for its injectables business as it expects it to grow to a $650-700 million revenue business by FY24 from current $400 million per annum. Aurobindo Pharma plans around 10-15 product launches in the segment in FY23, which is expected to drive growth for FY23E and FY24E.

Click on the attachment for the full list of KRChoksey’s top stock picks for May:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.